Alloy Therapeutics
Biotechnology ecosystem company providing integrated discovery technologies, services, and platform access across multiple biologic modalities (antibodies, bispecifics, TCRs/TCR mimics, genetic medicines, peptides, and cell therapies). Operates humanized transgenic mouse discovery platforms, antigen generation and QC, high-throughput wet-lab and analytical workflows, and AI/ML-driven sequence design and repertoire mining. Offers platform licensing, subscription access models, venture-studio and joint-venture support, and regional centers of excellence for iPSC-derived cell therapy development.
Industries
Nr. of Employees
small (1-50)
Alloy Therapeutics
Services
End-to-end monoclonal discovery including in vivo immunization, B-cell recovery, deep sequencing, AI/ML repertoire mining, sequence prioritization, and functional characterization for therapeutic antibody lead identification.
Modular discovery of monoclonal arms, format engineering, high-throughput expression of bispecific panels, and customized functional screening cascades to deliver rank-ordered bispecific leads.
AI/ML-guided in silico design coupled with high-throughput expression and characterization to optimize affinity, specificity, developability, immunogenicity, and Fc properties.
Comprehensive discovery and engineering services for engineered TCRs and TCR-mimic proteins, including peptide–MHC complex production, specificity testing, affinity maturation, and preclinical characterization.
Design and discovery of antisense oligonucleotide therapeutics using engineered oligonucleotide chemistries and formats intended to improve potency, safety, and delivery (including applications for CNS targets).
Development and scale-up support for iPSC-derived off-the-shelf cell therapy platforms, including CAR and TCR engineering, hypoimmune features, and platform enhancement toward clinical translation.
End-to-end monoclonal discovery including in vivo immunization, B-cell recovery, deep sequencing, AI/ML repertoire mining, sequence prioritization, and functional characterization for therapeutic antibody lead identification.
Modular discovery of monoclonal arms, format engineering, high-throughput expression of bispecific panels, and customized functional screening cascades to deliver rank-ordered bispecific leads.
AI/ML-guided in silico design coupled with high-throughput expression and characterization to optimize affinity, specificity, developability, immunogenicity, and Fc properties.
Comprehensive discovery and engineering services for engineered TCRs and TCR-mimic proteins, including peptide–MHC complex production, specificity testing, affinity maturation, and preclinical characterization.
Design and discovery of antisense oligonucleotide therapeutics using engineered oligonucleotide chemistries and formats intended to improve potency, safety, and delivery (including applications for CNS targets).
Development and scale-up support for iPSC-derived off-the-shelf cell therapy platforms, including CAR and TCR engineering, hypoimmune features, and platform enhancement toward clinical translation.
Expertise Areas
- In vivo antibody discovery using humanized transgenic models
- Antigen generation and tailored immunization strategies
- B-cell recovery, repertoire sequencing, and informatics
- AI/ML-driven protein and antibody design
Key Technologies
- Humanized transgenic mouse discovery platforms
- Antigen production and QC for protein, cell-based, and genetic formats
- LNP mRNA and DNA immunization methods
- RIMMS and tolerance‑breaking immunization protocols
News & Updates
Public R&D event featuring presentations and panels on recent advancements across antibodies, bispecifics, TCR mimics, and genetic medicines; held in Cambridge, MA.
Company roadmap describing expansion of discovery technologies and services across multiple modalities, including plans for new transgenic strains, common-light-chain mice for bispecifics, TCR discovery expansion, and genetic medicines offerings.
Closed a $75 million Series C financing to advance platforms and resources used by scientific entrepreneurs to turn ideas into biological medicines.
Closed $42 million in Series D financing to accelerate discovery technology development across biologic modalities and expand pre-competitive offerings.
Strategic collaboration and license agreement to develop iPSC-derived CAR-T and CAR-NK platforms; the company obtained co-exclusive commercialization rights for oncology indications.
Collaboration and license agreement to apply engineered antisense formats to a CNS target with upfront and potential milestone payments and royalties.
Public R&D event featuring presentations and panels on recent advancements across antibodies, bispecifics, TCR mimics, and genetic medicines; held in Cambridge, MA.
Company roadmap describing expansion of discovery technologies and services across multiple modalities, including plans for new transgenic strains, common-light-chain mice for bispecifics, TCR discovery expansion, and genetic medicines offerings.
Closed a $75 million Series C financing to advance platforms and resources used by scientific entrepreneurs to turn ideas into biological medicines.
Closed $42 million in Series D financing to accelerate discovery technology development across biologic modalities and expand pre-competitive offerings.
Strategic collaboration and license agreement to develop iPSC-derived CAR-T and CAR-NK platforms; the company obtained co-exclusive commercialization rights for oncology indications.
Collaboration and license agreement to apply engineered antisense formats to a CNS target with upfront and potential milestone payments and royalties.